Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-378/Ritonavir and Efavirenz in PI-Experienced HIV
NCT00004582Phase 2
Key facts
- Status
- Completed
- Countries
- 1
- Modality
- Orthosteric Ligands
- Drugs
- lopinavir
- Conditions
- human immunodeficiency virus infection (HIV)
01
Overview
Phase 2, open-label, single-arm trial of lopinavir in human immunodeficiency virus infection (HIV). Status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
ABT-378/ritonavir + Efavirenz
All patients receive ABT-378/ritonavir and efavirenz for 48 weeks.
03
Who it enrols
HIV-positive patients with viral load >= 1,000 copies/ml who are experienced with multiple protease inhibitors but naive to NNRTIs.
Beyond the preview
Go deeper on NCT00004582.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004582.